Virnext congratulates AIS Biotech on successfully raising €1.5 million to advance the development of its innovative therapies for infectious diseases. This funding will support the preclinical development of GlycoFlu, their novel drug candidate for influenza, and strengthen their technological platform for sugar-based bioproduction, designed to target additional pathogens. This milestone reflects the confidence of AIS Biotech’s partners and investors in the company’s strategy and technological approach.
This achievement marks a significant step forward in AIS Biotech’s mission to develop sugars as future therapeutic tools to combat infectious diseases and antibiotic resistance. Virnext is pleased to support AIS Biotech in this initiative, which highlights scientific innovation, translational research, and societal impact.
